Cargando…
HER2 as a target in invasive urothelial carcinoma
We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), D...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472207/ https://www.ncbi.nlm.nih.gov/pubmed/25720673 http://dx.doi.org/10.1002/cam4.432 |
_version_ | 1782377021537517568 |
---|---|
author | Bellmunt, Joaquim Werner, Lillian Bamias, Aristotle Fay, André P Park, Rachel S Riester, Markus Selvarajah, Shamini Barletta, Justine A Berman, David M de Muga, Silvia Salido, Marta Gallardo, Enrique Rojo, Federico Guancial, Elizabeth A Bambury, Richard Mullane, Stephanie A Choueiri, Toni K Loda, Massimo Stack, Edward Rosenberg, Jonathan |
author_facet | Bellmunt, Joaquim Werner, Lillian Bamias, Aristotle Fay, André P Park, Rachel S Riester, Markus Selvarajah, Shamini Barletta, Justine A Berman, David M de Muga, Silvia Salido, Marta Gallardo, Enrique Rojo, Federico Guancial, Elizabeth A Bambury, Richard Mullane, Stephanie A Choueiri, Toni K Loda, Massimo Stack, Edward Rosenberg, Jonathan |
author_sort | Bellmunt, Joaquim |
collection | PubMed |
description | We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), DNA copy number, mRNA expression, and mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival. ERBB2 mutation was determined by hotspot sequencing. mRNA expression was assessed using NanoString counting. Association of overall survival (OS) and HER2 status was assessed by a Cox regression model. NIH-3T3 cells containing HER2 V777L were assessed for growth, invasion, and HER2 kinase activation. In all, 22% of Spanish and 4% of Greek cohorts had 3+ HER2 staining by IHC. FISH amplification was identified in 20% of Spanish and 4% of Greek cohorts. Kappa coefficient between FISH and IHC was 0.47. HER2 status was not associated with OS in univariate (Spanish P = 0.34; Greek P = 0.11) or multivariate (Spanish P = 0.49; Greek P = 0.12) analysis. HER2-positive tumors expressed higher levels of HER2 mRNA than HER2-negative tumors (P < 0.001). HER2 mutations (V777L and L755S) were identified in two (2%) patients. In vitro analysis of V777L results in transformation of NIH-3T3 cells, leading to increased growth, invasion on soft agar, and HER2 kinase constitutive activation. In summary, HER2 overexpression or amplification in the primary tumor did not predict OS in patients with metastatic UC. HER2 positivity rates can differ between different populations. Further trials in genomically screened patients are needed to assess HER2-targeted therapies in UC. |
format | Online Article Text |
id | pubmed-4472207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44722072015-06-23 HER2 as a target in invasive urothelial carcinoma Bellmunt, Joaquim Werner, Lillian Bamias, Aristotle Fay, André P Park, Rachel S Riester, Markus Selvarajah, Shamini Barletta, Justine A Berman, David M de Muga, Silvia Salido, Marta Gallardo, Enrique Rojo, Federico Guancial, Elizabeth A Bambury, Richard Mullane, Stephanie A Choueiri, Toni K Loda, Massimo Stack, Edward Rosenberg, Jonathan Cancer Med Cancer Research We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), DNA copy number, mRNA expression, and mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival. ERBB2 mutation was determined by hotspot sequencing. mRNA expression was assessed using NanoString counting. Association of overall survival (OS) and HER2 status was assessed by a Cox regression model. NIH-3T3 cells containing HER2 V777L were assessed for growth, invasion, and HER2 kinase activation. In all, 22% of Spanish and 4% of Greek cohorts had 3+ HER2 staining by IHC. FISH amplification was identified in 20% of Spanish and 4% of Greek cohorts. Kappa coefficient between FISH and IHC was 0.47. HER2 status was not associated with OS in univariate (Spanish P = 0.34; Greek P = 0.11) or multivariate (Spanish P = 0.49; Greek P = 0.12) analysis. HER2-positive tumors expressed higher levels of HER2 mRNA than HER2-negative tumors (P < 0.001). HER2 mutations (V777L and L755S) were identified in two (2%) patients. In vitro analysis of V777L results in transformation of NIH-3T3 cells, leading to increased growth, invasion on soft agar, and HER2 kinase constitutive activation. In summary, HER2 overexpression or amplification in the primary tumor did not predict OS in patients with metastatic UC. HER2 positivity rates can differ between different populations. Further trials in genomically screened patients are needed to assess HER2-targeted therapies in UC. BlackWell Publishing Ltd 2015-06 2015-02-26 /pmc/articles/PMC4472207/ /pubmed/25720673 http://dx.doi.org/10.1002/cam4.432 Text en © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Research Bellmunt, Joaquim Werner, Lillian Bamias, Aristotle Fay, André P Park, Rachel S Riester, Markus Selvarajah, Shamini Barletta, Justine A Berman, David M de Muga, Silvia Salido, Marta Gallardo, Enrique Rojo, Federico Guancial, Elizabeth A Bambury, Richard Mullane, Stephanie A Choueiri, Toni K Loda, Massimo Stack, Edward Rosenberg, Jonathan HER2 as a target in invasive urothelial carcinoma |
title | HER2 as a target in invasive urothelial carcinoma |
title_full | HER2 as a target in invasive urothelial carcinoma |
title_fullStr | HER2 as a target in invasive urothelial carcinoma |
title_full_unstemmed | HER2 as a target in invasive urothelial carcinoma |
title_short | HER2 as a target in invasive urothelial carcinoma |
title_sort | her2 as a target in invasive urothelial carcinoma |
topic | Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472207/ https://www.ncbi.nlm.nih.gov/pubmed/25720673 http://dx.doi.org/10.1002/cam4.432 |
work_keys_str_mv | AT bellmuntjoaquim her2asatargetininvasiveurothelialcarcinoma AT wernerlillian her2asatargetininvasiveurothelialcarcinoma AT bamiasaristotle her2asatargetininvasiveurothelialcarcinoma AT fayandrep her2asatargetininvasiveurothelialcarcinoma AT parkrachels her2asatargetininvasiveurothelialcarcinoma AT riestermarkus her2asatargetininvasiveurothelialcarcinoma AT selvarajahshamini her2asatargetininvasiveurothelialcarcinoma AT barlettajustinea her2asatargetininvasiveurothelialcarcinoma AT bermandavidm her2asatargetininvasiveurothelialcarcinoma AT demugasilvia her2asatargetininvasiveurothelialcarcinoma AT salidomarta her2asatargetininvasiveurothelialcarcinoma AT gallardoenrique her2asatargetininvasiveurothelialcarcinoma AT rojofederico her2asatargetininvasiveurothelialcarcinoma AT guancialelizabetha her2asatargetininvasiveurothelialcarcinoma AT bamburyrichard her2asatargetininvasiveurothelialcarcinoma AT mullanestephaniea her2asatargetininvasiveurothelialcarcinoma AT choueiritonik her2asatargetininvasiveurothelialcarcinoma AT lodamassimo her2asatargetininvasiveurothelialcarcinoma AT stackedward her2asatargetininvasiveurothelialcarcinoma AT rosenbergjonathan her2asatargetininvasiveurothelialcarcinoma |